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The IGF-I receptor (IGF-IR) has been studied as an anti-cancer target. However, monother-
apy trials with IGF-IR targeted antibodies or with IGF-IR specific tyrosine kinase inhibitors
have, overall, been very disappointing in the clinical setting. This review discusses poten-
tial reasons why IGF-I R targeted therapy fails to inhibit growth of human cancers. It has
become clear that intracellular signaling pathways are highly interconnected and complex
instead of being linear and simple. One of the most potent candidates for failure of IGF-IR
targeted therapy is the insulin receptor isoform A (IR-A). Activation of the IR-A by insulin-
like growth factor-II (IGF-II) bypasses the IGF-IR and its inhibition. Another factor may be
that anti-cancer treatment may reduce IGF-IR expression. IGF-IR blocking drugs may also
induce hyperglycemia and hyperinsulinemia, which may further stimulate cell growth. In
addition, circulating IGF-IRs may reduce therapeutic effects of IGF-IR targeted therapy. Nev-
ertheless, it is still possible that the IGF-IR may be a useful adjuvant or secondary target
for the treatment of human cancers. Development of functional inhibitors that affect the
IGF-IR and IR-A may be necessary to overcome resistance and to make IGF-IR targeted
therapy successful. Drugs that modify alternative downstream effects of the IGF-IR, so
called “biasing agonists,” should also be considered.
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hyperglycemia
THE RELATIONSHIP BETWEEN IGF-I AND CANCER
Activation of the insulin-like growth factor-I receptor (IGF-IR)
pathway has been found to be essential for initiation and growth of
cancers (1). Many types of tumor cells often overexpress IGF-IRs
(1). In addition, surrounding stromal tissue of tumor cells pro-
duces IGF-I and IGF-II (2) and activation of the IGF-IRs of tumor
cells may be mediated by IGFs in a paracrine and autocrine way
(3). Prospective studies suggest that individuals with circulating
IGF-I concentrations at the high end of the normal range have an
increased risk for several common cancers (1, 4). In many tumors,
binding of IGF-I and IGF-II to the IGF-IR, inhibits apoptosis and
promotes cell proliferation (5). In the last years, insulin has been
also associated with the development of cancer in subjects with
type 2 diabetes. Although all the underlying mechanisms need to
be clarified, it has been suggested that hyperinsulinemia upreg-
ulates growth hormone receptor (GHR) expression and thereby
upregulates hepatic IGF-I production (6). In addition, hyperinsu-
linemia also suppresses the levels of IGFBP1 and IGFBP2, thereby
increasing IGF-I bioavailability (7).
THE COMPLEXITY OF THE INSULIN-IGF FAMILY
The insulin-IGF family comprises a complex molecular signaling
pathway (8). Depending on which regions are being compared,
the IR and IGF-IR have sequence similarities varying from 41
to 84% (9). Both the IR and IGF-IR belong to the family of
ligand-activated receptor kinases. The gene coding for the IR is
localized on chromosome 19 and is composed of 22 exons (10,
11). Alternative mRNA splicing results in the expression of two
isoforms: one containing exon 11 (the “classical” IR-B) and one
missing exon 11 (the IR-A) (12). Exon 11 encodes for 12 amino
acids localized at the C-terminal part of the alpha chain of the
IR. Deletion of this exon has important functional consequences:
IR-A has high affinity for insulin and IGF-II but binds IGF-I with
low affinity. IR-A binds insulin with 1.5-fold higher affinity than
IR-B and possesses a higher dissociation and internalization rate
(13). Therefore, in cells with increased IR-A: IR-B ratios, insulin
mainly signals through IR-A (14). IR-B is responsible for the clas-
sic metabolic responses induced by insulin, and also binds IGF-I
and IGF-II with low and intermediate affinity, respectively (15).
The expression profile of both IR isoforms is tissue-specific (12,
16). Interestingly, an increase in the IR-A to IR-B ratio have been
reported in type 2 diabetes (17, 18).
All this information is mainly obtained by measurements of
mRNA levels of IR-A and IR-B in different tissues. However, at
present there is no good information about the exact expression
of protein levels of IR-A and IR-B at the cell surface due to a lack
of antibodies which can distinguish both isoforms of the IR.
In contrast to insulin, most of the IGFs in the circulation and in
other extracellular fluids, form complexes to six high-affinity IGF-
binding proteins (IGFBPs) (5). IGFBPs regulate the half-life and
bioavailability of IGF-I and IGF-II and modulate their accessibility
to the receptor (19). Under physiological circumstances but also in
cancers partial proteolysis of IGFBP-3 and other IGFBPs may be
an important mechanism for regulating IGF-I bioavailability (20).
THE ROLE OF IGF-INSULIN HYBRID RECEPTORS AND THEIR
CROSS-TALK WITH OTHER RECEPTORS
Since most mammalian cells express both the IGF-IR and the IR,
although at different expression levels, functional heterodimers
can form between the IGF-IR and IR isoforms (15). A significant
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fraction of both IRs and IGF-IRs is present as hybrids in most
mammalian tissues, including those that are considered to be clas-
sic targets of insulin (21). The IR-A/IGF-IR hybrids bind insulin
and both IGFs with similar affinity, whereas IR-B/IGF-IR hybrids
mainly behave like an IGF-IR, with high affinity for IGF-I, low
affinity for IGF-II, and insignificant affinity for insulin (22). Slaaby
et al. postulated that a possible explanation for this latter phenom-
enon may be that to achieve high-affinity binding, IGF-I requires
a receptor monomer, while insulin requires a homodimeric IR
(23). Thus, IGF-I may bind to the IGF-IR half of a hybrid recep-
tor irrespective of what the molecular structure of the other half
receptor is, while insulin requires a homodimeric IR to achieve
this (23). Both IGFs and insulin stimulated cell proliferation and
migration more effectively in cells containing IGF-IR/IR-A hybrids
than in cells containing IGF-IR/IR-B hybrids (22). When consider-
ing all possible combinations of homodimer and hybrid receptors
of the insulin/IGF signaling pathway, there are at least six tyro-
sine kinase receptors potentially involved in signal transduction
(Figure 1).
The IR/IGF-IR signaling pathway also has extensive cross-talk
with the GHR, estrogen receptor (ER), androgen receptor (AR),
epidermal growth factor receptor (EGFR), and human epidermal
growth factor receptor 2 (HER-2) signaling pathways (24–27) (see
below). On the other hand EGFR mediated growth requires the
presence of functional IGF-IRs for its mitogenic activities (28).
While IGF-IR can heterodimerize with the IRs, as discussed
above, it can also form heterodimers with receptors from other
families (8). For example, the IGF-IR may form a heterodimer
with the EGFR (29). Inhibition of one receptor in these hybrids
may shift the signaling pathway in favor of the other available
counterpart receptor (8, 30, 31).
STRATEGIES TO TARGET THE IGF-IR IN CANCER
Specific signaling pathway (like IGF-IR pathway) dependence of
certain cancers creates, at least theoretically, an Achilles heel for
tumor maintenance, which can be exploited therapeutically (32).
As an anti-cancer target, the IGF-IR has been studied in many
clinical trials over the past years (33). Three major strategies have
FIGURE 1 |When considering all possible combinations of homodimer
and hybrid receptors of the insulin/IGF signaling pathway, there are at
least six potentially tyrosine kinase receptors involved in signal
transduction.
been used: (1) monoclonal antibodies against the IGF-IR, (2)
monoclonal antibodies against IGF-I or IGF-II, and (3) tyrosine
kinase inhibitors of the IGF-IR (33). Monoclonal IGF-IR anti-
bodies block ligand binding and induce receptor internalization
and degradation (34). As a class effect, IGF-IR blocking drugs
cause insulin resistance, hyperinsulinemia, and (often mild and
reversible) hyperglycemia (35). Besides through decreased IGF-
I action, insulin resistance induced by IGF-IR blocking drugs is
also thought to be caused by an increased secretion of GH and
some IGFBPs (36). The increased GH secretion is the result of
a direct blockade of the pituitary IGF-IRs by these agents (36).
Monoclonal antibodies against IGF-I or IGF-II act by neutral-
izing IGF-I and IGF-II, preventing receptor activation without
affecting glucose tolerance (37). The majority of IGF-IR tyrosine
kinase inhibitors act by competing with ATP for binding in the
IGF-IR kinase domain, although also non-competitive agents are
being developed (37). They may induce hyperglycemia by direct
inhibition of IR-kinase (37).
Although, initially promising effects have been reported in
phase 2 trials, more extensive experience has learned that a poten-
tial clinical benefit for monotherapies blocking IGF-I or the IGF-IR
is only limited to a small subset of patients with specific cancers
(sarcoma, Ewing sarcoma non-small cell lung cancer and some
other chemotherapy-refractory solid tumors) (38–40), while the
majority of studies have been disappointing and have failed to
show any clinical benefit in the treatment of cancers (33). In
the next sections, we will discuss some background and possible
reasons for the failure of these therapies.
THE FEASIBILITY OF THE IGF-IR AS ANTI-CANCER TARGET
Recent DNA and RNA sequencing projects have revealed recurrent
somatic alterations in several genes that are drivers of oncogenesis.
Most cancers contain many mutations and are thus not dependent
on one single oncogenic mutation (32). They activate RAS, BRAF,
EGFR, and many others. These driver alterations can give rise to a
tumor dependency on a particular signaling pathway (32). How-
ever, in clinical settings no cancer specific mutations of the IGF-IR
or its ligands have been described to date (41). Moreover, the IGF-
IRs of cancer cells also do not contain intrinsic (post) receptor
abnormalities (42).
Owing to the presence of an intracellular tyrosine kinase
domain, the IGF-IR is usually classified as a tyrosine kinase recep-
tor. Accordingly, phosphorylation was until very recently, consid-
ered to be the central process governing IGF-IR signaling (42). As
a consequence, to date most therapies targeting the IGF-IR have
mainly been designed aiming to block phosphorylation mediated
signaling by preventing receptor–ligand interaction or by limiting
kinase activation (42).
CONSEQUENCES OF IGF-IR TARGETED THERAPY IN CANCER
The common mechanisms of action of IGF-IR targeted antibod-
ies are that they block the IGF-IR from ligand binding and induce
internalization/degradation of the IGF-IR (43). Most developed
antibodies directed against the IGF-IR are highly specific for the
IGF-IR and do not bind to IRs. Nevertheless, it has been found
that antibodies directed against the IGF-IR may not only down-
regulate IGF-IR homodimers but also the IGF-IR/IR hybrids (44).
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Interestingly, in a model of prostate cancer, following IGF-IR
inhibition, the IR was able to compensate for and mediate IGF-
I induced mitogenic signaling (45). Moreover, in breast cancer
cells, downregulation of IGF-IRs by siRNA sensitized these cells to
insulin-mediated activation of intracellular downstream signaling
pathways (46).
MECHANISMS RESPONSIBLE FOR FAILURE OF IGF-IR
DIRECTED THERAPY
The following reasons for the failure of IGF-IR targeted therapy to
inhibit the growth of human cancers have been suggested (47):
(1) Mutations in PI3K (or PTEN deletions) constitutively activate
Akt (and subsequent cell cycle progression genes) and render
cells resistant to IGF-IR targeted therapy. This has not been
proven so far.
(2) Targeting the IGF-IR in some cells (e.g., hematopoietic pre-
cursors and neuronal cells) could actually inhibit a tendency
to differentiation.
(3) An increased IR-A cell surface expression upon downregu-
lation of IGF-IR signaling. The Vignieri–Belfiori group has
convincingly demonstrated that stimulation of the IR-A –
especially by IGF-II – may induce mitogenic signals and
replace IGF-IR signaling in human tumors (13, 47). Thus acti-
vation of the IR-A by IGF-II bypasses IGF-IR signaling and its
inhibition.
(4) Anti-cancer treatment may cause a reduction of IGF-IR
expression at the cellular membrane. For example, treatment
of human breast tumors with the anti-estrogen tamoxifen
causes reduction in membranous IGF-IR expression (48). A
reduction in membranous IGF-IR expression may occur as an
adaptive resistance mechanism and this may play an impor-
tant role in the inability to sustain IGF-IR blockade (8). In
addition, absence of N -linked glycosylation has been reported
to change insertion of the IGF-IR into the cell membrane and
induces resistance to IGF-IR directed antibodies (49). Nuclear
translocation of the IGF-IR may be another factor, which lim-
its accessibility and actions of IGF-IR directed antibodies. On
the other hand, exclusive nuclear localization of IGF-IR has
been reported to be associated with a better response when
patients were treated with IGF-IR targeted antibodies (50).
(5) Most important is the complexity of regulatory mechanisms
in cancer cells, including the existence of subpopulations in
each cancer with different mutations and sensitivities. As dis-
cussed in the previous paragraph, the IGF system is not a
unique tumor driver and each of these subpopulations can be
regulated by a variety of genes and large and small non-coding
RNAs (the “dark matter” of cellular function) (47). Moreover,
signaling pathways in cells are interconnected and these inter-
actions are dynamic in time (51). It has become clear that all
pathways previously thought to be linear are in fact highly
interconnected into complex signaling pathways (32). Recep-
tor cross-talk can occur through ligand interactions or via
common downstream molecular pathways and modulation
(8). This cross-talk gives tumors additional signaling oppor-
tunities and the potential to evade regulatory checkpoints
(8). For example, the inhibition of the IGF-1R pathway by
cixutumumab results in stimulation of the Akt/mTOR path-
way by increasing synthesis of EGFR, Akt1, and antiapoptotic
surviving proteins (52).
As discussed above, IGF-IR blocking drugs may also induce
hyperglycemia, hyperinsulinemia, and an increased GH secretion.
This may paradoxically contribute to proliferation of tumor cells
by several mechanisms:
(1) Although phosphorylation of IGF-IR tyrosine residues is gen-
erally considered to be the initial activation step within the
intracellular IGF-IR signaling pathway, it has been found that
cells undergo a signaling switch under hyperglycemic condi-
tions (53). After this switch, a completely different mechanism
is utilized to activate mitogenic pathways downstream of the
IGF-IR and this activation is independent of IGF-IR tyrosine
phosphorylation (54).
(2) Secretion of insulin is mainly regulated by glucose lev-
els. IGF-IR blocking drugs increase glucose levels, which
may induce hyperinsulinemia and thereby tumor growth by
directly stimulating IR-A and indirectly by inducing resistance
to chemotherapy (55).
(3) An increased expression of the GHR is a characteristic of a
variety of human cancers while GH may induce tumor growth,
independent of IGF-I action (56).
Recently circulating IGF-IR levels were reported (57). We
hypothesize that circulating (soluble) IGF-IRs in cancer patients
may be another important factor responsible for the observed dis-
crepancy between in vitro and in vivo effects of IGF-IR targeted
therapy: antibodies against a tumor-target largely remain in the
blood and usually no more than 20% of the administered antibody
dose typically interacts with the tumor (58). Formation of com-
plexes between the soluble IGF-IRs and antibodies directed against
the IGF-IR may further reduce the amount of IGF-IR antibodies
leaving the circulation to interact with IGF-IRs expressed on the
surface of cancer cells (Figure 2A). In addition, these complexes
displace IGF-I and IGF-II from the circulating soluble IGF-IRs
thereby (paradoxically) increasing the amount of free IGF-I and
IGF-II that can leave the circulation to stimulate IGF-IRs displayed
on the surface of cancer cells (Figures 2B,C).
IS THERE STILL A POTENTIAL FOR IGF-IR TARGETED
THERAPY IN CANCER?
Given the complex signaling pathways that converge on those acti-
vated by the IGF-IR, it is not surprising that for most cancers
IGF-IR targeted monotherapy in vivo has been disappointing (8,
59). Although IGF-IR targeted monotherapy has essentially been
abandoned, it is still possible that targeting the IGF-IR may have
an important role as adjuvant treatment of human cancers (47)
(see below).
Since the IGF-IR has extensive cross-talk with other recep-
tor tyrosine kinases and their downstream effectors, inhibition
of the IGF-IR by a specific antibody may be compensated by
other pathways (37). The most obvious candidates responsible for
this compensation are the IR-A and IGF-II. In vitro, we recently
showed that circulating IGF-II may contribute substantially to
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FIGURE 2 | Circulating IGF-I receptors in cancer patients may form
complexes with IGF-IR directed antibodies and this may reduce
therapeutic effects of IGF-I receptor antibodies in vivo: (A) In the
circulation soluble IGF-I receptors and antibodies directed against the
IGF-IR may form complexes. This may limit the availability of IGF-IR
antibodies leaving the circulation and reduce the amount of IGF-IR
antibodies leaving the circulation to inhibit IGF-I receptors present at the
cell surface of cancer cells. (B) Only “free” IGF-I and IGF-II may leave the
circulation to bind to IGF-I receptors present at the cell surface of cancer
cells. Complexes formed between the IGFs and the soluble IGF-Rs are to
big to pass the vessel wall and to leave the circulation. (C) Formation of
complexes between IGF-IR directed antibodies and soluble IGF-IR displace
IGF-I and IGF-II from the soluble IGF-I receptors thereby (paradoxically)
increasing the total amount of free IGF-I and IGF-II that can leave the
circulation to stimulate IGF receptors displayed at the cell surface of
cancer cells.
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IR-A and IR-B signaling (60). It has been also suggested that
therapeutic interventions of cancers may trigger a phenotype
switch in surviving cells to a more primitive and immature cell
state (61). In favor of this latter possibility, as discussed above, the
IR-A and IGF-II are frequently highly expressed by human tumors.
In addition, there is further evidence that resistance to IGF-IR
directed therapy is the direct result from formation of IGF-I/IR-
A hybrids and IGF-II signaling via the IR-A isoform (37). Thus
the development of functional inhibitors that affect IGF-IR and
IR-A may be necessary to overcome resistance to IGF-IR directed
therapy.
On the other hand, IGF-IR blocking therapy is expected to
be most effective in tumors with increased IGF-IR and poor IR-
activation. Thus, identification of a subset of patients most likely
to benefit from IGF signaling interference should be pursued.
Combining the diagnostic and therapeutic potential of an anti-
body, thereby selecting those patients who are most likely to
benefit from antibody treatment, could be an important step to
improve IGF-IR targeted therapy (62). In contrast to immuno-
histochemical imaging of the IGF-IR, molecular IGF-IR imag-
ing (for example 111In-R1507 SPECT) in vivo might be able to
predict and to identify who will benefit from IGF-IR targeted
therapy (63).
Combining IGF-IR targeted therapy to chemotherapy may
be another potential successful strategy since IGF-I may protect
tumor cells from being killed by cytotoxic drugs (37, 64). In addi-
tion, this may help to suppress chemotherapy induced IGF-IR
activation and DNA repair mechanisms (37). Furthermore, the
feasibility and timing of combining multiple targeted therapies
(IGF-IR and IR-A) and conventional cytotoxic drugs need to be
explored. Recently it was suggested that the IGF-IR also behaves
like a functional receptor tyrosine kinase/G-protein related cou-
pled receptor (GPCR) hybrid “borrowing” components of GPCR
signaling (42). As a consequence, the IGF-IR (and IR) can acti-
vate signaling as a GPCR, using different G-proteins (42). IGF-I
activity and its biological effects are further controlled by a vari-
ety of adaptor proteins/signaling proteins through IGF-IR post-
translational modifications including tyrosine and serine phos-
phorylation, dephosphorylation, ubiquitination, and sumoylation
(42). Therefore potential drugs that modify alternative down-
stream effects of the IGF-IR, the “biasing agonists,” should also
be considered (42).
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